Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer.

Khasnis MD, Halkidis K, Bhardwaj A, Root MJ.

PLoS Pathog. 2016 Dec 19;12(12):e1006098. doi: 10.1371/journal.ppat.1006098. eCollection 2016 Dec.

2.

Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus.

Leslie GJ, Wang J, Richardson MW, Haggarty BS, Hua KL, Duong J, Secreto AJ, Jordon AP, Romano J, Kumar KE, DeClercq JJ, Gregory PD, June CH, Root MJ, Riley JL, Holmes MC, Hoxie JA.

PLoS Pathog. 2016 Nov 17;12(11):e1005983. doi: 10.1371/journal.ppat.1005983. eCollection 2016 Nov.

3.

A Homolog Pentameric Complex Dictates Viral Epithelial Tropism, Pathogenicity and Congenital Infection Rate in Guinea Pig Cytomegalovirus.

Coleman S, Choi KY, Root M, McGregor A.

PLoS Pathog. 2016 Jul 7;12(7):e1005755. doi: 10.1371/journal.ppat.1005755. eCollection 2016 Jul.

4.

A Novel Non-Replication-Competent Cytomegalovirus Capsid Mutant Vaccine Strategy Is Effective in Reducing Congenital Infection.

Choi KY, Root M, McGregor A.

J Virol. 2016 Aug 12;90(17):7902-19. doi: 10.1128/JVI.00283-16. Print 2016 Sep 1.

5.

Evaluation of the efficiency of human immune system reconstitution in NSG mice and NSG mice containing a human HLA.A2 transgene using hematopoietic stem cells purified from different sources.

Patton J, Vuyyuru R, Siglin A, Root M, Manser T.

J Immunol Methods. 2015 Jul;422:13-21. doi: 10.1016/j.jim.2015.02.007. Epub 2015 Mar 14.

6.

Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.

Rosemary Bastian A, Nangarlia A, Bailey LD, Holmes A, Kalyana Sundaram RV, Ang C, Moreira DR, Freedman K, Duffy C, Contarino M, Abrams C, Root M, Chaiken I.

J Biol Chem. 2015 Jan 2;290(1):529-43. doi: 10.1074/jbc.M114.608315. Epub 2014 Nov 4.

7.

Adding multiple risk factors improves Framingham coronary heart disease risk scores.

Hu G, Root M, Duncan AW.

Vasc Health Risk Manag. 2014 Sep 5;10:557-62. doi: 10.2147/VHRM.S69672. eCollection 2014.

8.

A randomized trial of fish oil omega-3 fatty acids on arterial health, inflammation, and metabolic syndrome in a young healthy population.

Root M, Collier SR, Zwetsloot KA, West KL, McGinn MC.

Nutr J. 2013 Apr 8;12:40. doi: 10.1186/1475-2891-12-40.

9.

Dual function of novel pollen coat (surface) proteins: IgE-binding capacity and proteolytic activity disrupting the airway epithelial barrier.

Bashir ME, Ward JM, Cummings M, Karrar EE, Root M, Mohamed AB, Naclerio RM, Preuss D.

PLoS One. 2013;8(1):e53337. doi: 10.1371/journal.pone.0053337. Epub 2013 Jan 7.

10.

Polyvalent side chain peptide-synthetic polymer conjugates as HIV-1 entry inhibitors.

Danial M, Root MJ, Klok HA.

Biomacromolecules. 2012 May 14;13(5):1438-47. doi: 10.1021/bm300150q. Epub 2012 Apr 27.

11.

Combined fruit and vegetable intake is correlated with improved inflammatory and oxidant status from a cross-sectional study in a community setting.

Root MM, McGinn MC, Nieman DC, Henson DA, Heinz SA, Shanely RA, Knab AM, Jin F.

Nutrients. 2012 Jan;4(1):29-41. doi: 10.3390/nu4010029. Epub 2012 Jan 4.

12.

Nucleoporin Nup50 stabilizes closed conformation of armadillo repeat 10 in importin α5.

Pumroy RA, Nardozzi JD, Hart DJ, Root MJ, Cingolani G.

J Biol Chem. 2012 Jan 13;287(3):2022-31. doi: 10.1074/jbc.M111.315838. Epub 2011 Nov 30.

13.

Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance.

Welch BD, Francis JN, Redman JS, Paul S, Weinstock MT, Reeves JD, Lie YS, Whitby FG, Eckert DM, Hill CP, Root MJ, Kay MS.

J Virol. 2010 Nov;84(21):11235-44. doi: 10.1128/JVI.01339-10. Epub 2010 Aug 18.

14.

Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding.

Kahle KM, Steger HK, Root MJ.

PLoS Pathog. 2009 Nov;5(11):e1000674. doi: 10.1371/journal.ppat.1000674. Epub 2009 Nov 26.

15.

Synthesis analysis of regression models with a continuous outcome.

Zhou XH, Hu N, Hu G, Root M.

Stat Med. 2009 May 15;28(11):1620-35. doi: 10.1002/sim.3563.

16.

Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection.

Lederman MM, Jump R, Pilch-Cooper HA, Root M, Sieg SF.

Retrovirology. 2008 Dec 18;5:116. doi: 10.1186/1742-4690-5-116. Review.

17.

Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.

Champagne K, Shishido A, Root MJ.

J Biol Chem. 2009 Feb 6;284(6):3619-27. doi: 10.1074/jbc.M809269200. Epub 2008 Dec 10.

18.

Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain.

Adekar SP, Takahashi T, Jones RM, Al-Saleem FH, Ancharski DM, Root MJ, Kapadnis BP, Simpson LL, Dessain SK.

PLoS One. 2008 Aug 20;3(8):e3023. doi: 10.1371/journal.pone.0003023.

20.

Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein.

Root MJ, Hamer DH.

Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5016-21. Epub 2003 Apr 17.

Supplemental Content

Loading ...
Support Center